{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:21:46Z","timestamp":1777396906761,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.amjcard.2025.01.016","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T01:32:37Z","timestamp":1737595957000},"page":"52-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The Efficacy and Safety of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"241","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3988-6211","authenticated-orcid":false,"given":"Chidubem","family":"Ezenna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrinal Murali","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghna","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Valania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Goldsweig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2025.01.016_bib0001","unstructured":"H Basit, MH Alahmadi, P Rout, S. Sharma, Hypertrophic Cardiomyopathy, [Updated 2024 Jun 7], StatPearls [Internet], 2024, StatPearls Publishing; Treasure Island (FL), Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430788\/#."},{"issue":"4","key":"10.1016\/j.amjcard.2025.01.016_bib0002","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjcard.2025.01.016_bib0003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","article-title":"Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine","volume":"64","author":"Maron","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"9862","key":"10.1016\/j.amjcard.2025.01.016_bib0004","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"The Lancet"},{"issue":"9","key":"10.1016\/j.amjcard.2025.01.016_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024656","article-title":"Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter","volume":"11","author":"Masri","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.amjcard.2025.01.016_bib0006","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jchf.2023.04.018","article-title":"Cardiac myosin inhibitors for managing obstructive hypertrophic cardiomyopathy: JACC: heart failure state-of-the-art review","volume":"11","author":"Ostrominski","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"39","key":"10.1016\/j.amjcard.2025.01.016_bib0007","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the european society of cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.amjcard.2025.01.016_bib0008","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: A report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjcard.2025.01.016_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101429","article-title":"Mavacamten treatment for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Ismayl","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.amjcard.2025.01.016_bib0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.amjcard.2023.10.059","article-title":"The efficacy of cardiac myosin inhibitors versus placebo in patients with symptomatic hypertrophic cardiomyopathy: a meta-analysis and systematic review","volume":"210","author":"Yassen","year":"2024","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.amjcard.2025.01.016_bib0011","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10741-023-10375-6","article-title":"A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy","volume":"29","author":"Yacoub","year":"2024","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjcard.2025.01.016_bib0012","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2025.01.016_bib0013","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.amjcard.2025.01.016_bib0014","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jrsm.1316","article-title":"A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses","volume":"10","author":"Langan","year":"2019","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.amjcard.2025.01.016_bib0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"11","key":"10.1016\/j.amjcard.2025.01.016_bib0016","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"21","key":"10.1016\/j.amjcard.2025.01.016_bib0017","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.amjcard.2025.01.016_bib0018","doi-asserted-by":"crossref","first-page":"A644","DOI":"10.1016\/S0735-1097(18)31185-9","article-title":"Reduction in left ventricular outflow tract gradient with MAVACAMTEN (MYK-461) in symptomatic obstructive hypertrophic cardiomyopathy patients (PIONEER-HCM)","volume":"71","author":"Jacoby","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10253","key":"10.1016\/j.amjcard.2025.01.016_bib0019","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.amjcard.2025.01.016_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.amjcard.2025.01.016_bib0021","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of Mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.amjcard.2025.01.016_bib0022","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.amjcard.2025.01.016_bib0023","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.amjcard.2025.01.016_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.033767","article-title":"Mavacamten for obstructive hypertrophic cardiomyopathy: rationale for clinically guided dose titration to optimize individual response","volume":"13","author":"Owens","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.amjcard.2025.01.016_bib0025","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s44161-024-00505-0","article-title":"Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy","volume":"3","author":"Hartman","year":"2024","journal-title":"Nat Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.amjcard.2025.01.016_bib0026","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.cjca.2024.01.022","article-title":"The revolution of cardiac myosin inhibitors in patients with hypertrophic cardiomyopathy","volume":"40","author":"Haraf","year":"2024","journal-title":"Can J Cardiol"},{"issue":"8","key":"10.1016\/j.amjcard.2025.01.016_bib0027","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jchf.2022.03.002","article-title":"Validation of the Kansas city cardiomyopathy questionnaire in symptomatic obstructive hypertrophic cardiomyopathy","volume":"10","author":"Nassif","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"21","key":"10.1016\/j.amjcard.2025.01.016_bib0028","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.01.016_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2024.08.014","article-title":"Effect of Aficamten on health status outcomes in obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM","author":"Sherrod","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.01.016_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM","author":"Desai","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.01.016_bib0031","series-title":"Mavacamten (CAMZYOS) National Drug Monograph","year":"2022"},{"issue":"11","key":"10.1016\/j.amjcard.2025.01.016_bib0032","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925000463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925000463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T12:57:10Z","timestamp":1742043430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914925000463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":32,"alternative-id":["S0002914925000463"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.01.016","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Efficacy and Safety of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}